Email this article Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice
- Authors: Sakaeva D.D1, Ruchkin V.V2, Goncharova O.V2, Abbasova R.R2, Mufazalov F.F2
-
Affiliations:
- Bashkir State Medical University
- Republican Clinical Oncology Center
- Issue: Vol 21, No 3 (2019)
- Pages: 21-25
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33512
- DOI: https://doi.org/10.26442/18151434.2019.3.190679
- ID: 33512
Cite item
Full Text
Abstract
In 2017 the first published PFS results of PACIFIC study demonstrated new opportunities of immunotherapy in locally-advanced unresectable non-small-cell lung cancer (NSCLC) after chemoradiation (CRT). The positive overall survival results in this trial were received next year. This trial has become the first positive study in the more then 10 years after failure of all trials which investigated different approaches for improvement efficacy of standard CRT (induction therapy, consolidation therapy, target therapy, increased RT dose). The PACIFIC trial has opened new opportunities to improve outcomes in this patient’s population. Durvalumab was registered in Russia in July 2019, however clinical experience of durvalumab administration is still limited and we need to build expertise in this field. In this article we present the first example of durvalumab therapy in post CRT period in Bashkortostan real clinical practices. Patient with IIIB st NSCLC started durvalumab therapy after standard CRT. The complete response was registered after 4 months of therapy and currently after 9 months of therapy it is still remain.
Full Text
##article.viewOnOriginalSite##About the authors
Dina D Sakaeva
Bashkir State Medical University
Email: d_sakaeva@mail.ru
D. Sci. (Med.) Ufa, Russia
Valerii V Ruchkin
Republican Clinical Oncology CenterCand. Sci. (Med.) Ufa, Russia
Olga V Goncharova
Republican Clinical Oncology CenterCand. Sci. (Med.) Ufa, Russia
Raliia R Abbasova
Republican Clinical Oncology CenterCand. Sci. (Med.) Ufa, Russia
Fagim F Mufazalov
Republican Clinical Oncology CenterD. Sci. (Med.) Ufa, Russia
References
- Злокачественные опухоли. Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). Под ред. В.М.Моисеенко. М.: Общероссийская общественная организация «Российское общество клинической онкологии», 2017. @@Malignant tumors. Cancer Medicines Practical Guidelines (RUSSCO). Pod red. V.M.Moiseenko. M.: Obshcherossiiskaia obshchestvennaia organizatsiia "Rossiiskoe obshchestvo klinicheskoi onkologii', 2017 (in Russian)
- Клинические рекомендации ESMO. Портал Европейского общества медицинской онкологии. URL: https://www.esmo.org/Guidelines/ESMO-Guidelines @@Klinicheskie rekomendatsii ESMO. Portal Evropeiskogo obshchestva meditsinskoi onkologii. URL: https://www.esmo.org/Guidelines/ESMO-Guidelines (in Russian)
- Клинические рекомендации. Рак лeгкого. Профессиональные ассоциации: Ассоциация онкологов России, Российское общество клинической онкологии. URL: http://cr.rosminzdrav.ru/ #!/schema/900 @@Klinicheskie rekomendatsii. Rak legkogo. Professional'nye assotsiatsii: Assotsiatsiia onkologov Rossii, Rossiiskoe obshchestvo klinicheskoi onkologii. URL: http://cr.rosminzdrav.ru/#!/schema/900 (in Russian)
- Senan S et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34: 953-62.
- Vokes E.E et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-704.
- Lilenbaum R et al. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III nonsmall cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 2015; 10: 143-7.
- Ahn J.S et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSGLU05-04. J Clin Oncol 2015; 33: 2660-6.
- Hanna N et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-60.
- Kelly K et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-6.
- Bradley J.D et al. Lancet Oncol 2015; 16: 187-99.
- Antonia S.J et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379: 2342-50.
- Jhanelle E. Gray, presented at the American Society of Clinical Oncology (ASCO). Annual Meeting; Chicago, IL, USA; May 31- June 4, 2019, poster 8526.
- Инструкция по применению лекарственного препарата для медицинского применения Имфинзи® (дурвалумаб). ЛП-005664-180719 от 18.07.2019. @@[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Imfinzi® (durvalumab). LP-005664-180719 ot 18.07.2019 (in Russian).]
- Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена, 2018. @@The status of cancer care for the population of Russia in 2017. Pod red. A.D.Kaprina, V.V.Starinskogo, G.V.Petrovoi. Moscow: MNIOI im. P.A.Gertsena, 2018 (in Russian)
